AbbVie (ABBV) Accounts Payables (2012 - 2026)
AbbVie (ABBV) posted quarterly Accounts Payables of $33.8 billion for Q1 2026, up 8.8% year-over-year from $31.0 billion in Q1 2025, and down 2.76% quarter-over-quarter from $34.7 billion in Q4 2025.
AbbVie (ABBV) Accounts Payables (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Accounts Payables for 15 consecutive years, with $33.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 8.8% year-over-year to $33.8 billion; the TTM figure through Mar 2026 stood at $33.8 billion (up 8.8% YoY), while the FY2025 annual figure was $34.7 billion, up 8.73% from the prior year.
- Accounts Payables retreated to $33.8 billion in Q1 2026 per ABBV's latest filing, from $34.7 billion in the prior quarter.
- Across five years, Accounts Payables topped out at $34.7 billion in Q4 2025 and bottomed at $22.5 billion in Q2 2022.
- Historically, Accounts Payables has averaged $29.1 billion across 5 years, with a median of $30.5 billion in 2024.
- Annual changes were most pronounced in 2024 — Accounts Payables gained 26.37% — and 2025, when it decreased 0.91%.
- AbbVie's Accounts Payables stood at $25.4 billion in 2022, then rose by 20.66% to $30.6 billion in 2023, then rose by 4.23% to $31.9 billion in 2024, then climbed by 8.73% to $34.7 billion in 2025, then decreased by 2.76% to $33.8 billion in 2026.
- Business Quant data shows ABBV's Accounts Payables at $33.8 billion in Q1 2026, $34.7 billion in Q4 2025, and $33.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.08 Bn | 633.32 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 470.80 Bn | 464.23 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 377.96 Bn | 370.82 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.49 Bn | 295.80 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.97 Bn | 253.07 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 236.98 Bn | 222.99 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 182.41 Bn | 179.23 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.49 Bn | 147.79 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 55.08 Bn | 47.70 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.30 Bn |
| Mar 31, 2026 | 33.77 Bn |
| Dec 31, 2025 | 34.73 Bn |
| Sep 30, 2025 | 33.62 Bn |
| Jun 30, 2025 | 32.25 Bn |
| Mar 31, 2025 | 31.04 Bn |
| Dec 31, 2024 | 31.95 Bn |
| Sep 30, 2024 | 30.49 Bn |
| Jun 30, 2024 | 29.33 Bn |
| Mar 31, 2024 | 31.33 Bn |
| Dec 31, 2023 | 30.65 Bn |
| Sep 30, 2023 | 29.66 Bn |
| Jun 30, 2023 | 27.04 Bn |
| Mar 31, 2023 | 24.79 Bn |
| Dec 31, 2022 | 25.40 Bn |
| Sep 30, 2022 | 23.51 Bn |
| Jun 30, 2022 | 22.54 Bn |
| Mar 31, 2022 | 22.57 Bn |
| Dec 31, 2021 | 22.70 Bn |
| Sep 30, 2021 | 21.86 Bn |